Good
Mostly Aligned
Patient Risk:
Low
Summary
The supplied claim about the boxed warning and close monitoring for suicidal thoughts/behaviors in pediatric/young adult patients is fully supported by the provided label excerpts (Boxed Warning, Section 5.1, 8.4, and 17). Other weight-change statements were not evaluated because the prompt’s label excerpts concern suicidal thoughts/behaviors.
Category Scores
Accurate Statements
Escitalopram’s label includes a warning that antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients, and advises close monitoring, especially during treatment initiation and dose changes.
BOXED WARNING: increased risk in pediatric and young adult patients in short-term studies; closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts/behaviors. Section 5.1: monitor especially during initial few months and at times of dosage changes; consider changing regimen/discontinuing if depression persists/worsens or emergent suicidal thoughts/behaviors occur. Section 8.4: reiterates increased risk in pediatric patients. Section 17: counsel to watch for emergence of suicidal ideation/behavior, especially during treatment and when dose is adjusted up or down.
Unsupported Statements
Escitalopram is an antidepressant medication.
Not supported or contradicted by the provided FDA label excerpts, which focus on suicidal thoughts/behaviors.
Escitalopram is primarily used to treat major depressive disorder.
Not supported or contradicted by the provided FDA label excerpts.
Escitalopram is primarily used to treat generalized anxiety disorder.
Not supported or contradicted by the provided FDA label excerpts.
According to clinical trials, escitalopram is not commonly associated with significant weight changes in patients.
Not supported or contradicted by the provided FDA label excerpts.
A 2014 study... did not cause significant weight loss...; mean weight loss of 0.2 kg over 8 weeks; another study found weight gain up to 1.5 kg; reviews on Drugs.com/CNS Spectrums described small/rare weight changes.
Not supported or contradicted by the provided FDA label excerpts.
Contradictions
Important Omissions
The claim does not mention the label’s statement that it is unknown whether the risk extends beyond four months, nor the counseling/clinical actions regarding considering changing the therapeutic regimen (including possibly discontinuing) if depression persists worse or suicidal thoughts/behaviors emerge.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated warning/monitoring claim is consistent with the provided boxed warning and Section 5.1/8.4/17 instructions. Other non-evaluated weight-related statements are not assessed against the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The claim partially omits additional label specifics about the uncertainty of longer-term risk extension and the label’s suggested clinical action (consider changing regimen/discontinuing if symptoms emerge).
Suggested Improvement
Include the label’s added specifics from Section 5.1 (e.g., unknown extension beyond four months; consider changing regimen including possibly discontinuing if depression worsens or suicidal thoughts/behaviors emerge) when describing the warning.